Journal Article

Identification of a melanoma susceptibility locus and somatic mutation in <i>TET2</i>

Fengju Song, Christopher I. Amos, Jeffrey E. Lee, Christine G. Lian, Shenying Fang, Hongliang Liu, Stuart MacGregor, Mark M. Iles, Matthew H. Law, Neal I. Lindeman, Grant W. Montgomery, David L. Duffy, Anne E. Cust, Mark A. Jenkins, David C. Whiteman, Richard F. Kefford, Graham G. Giles, Bruce K. Armstrong, Joanne F. Aitken, John L. Hopper, Kevin M. Brown, Nicholas G. Martin, Graham J. Mann, D.Timothy Bishop, Julia A.Newton Bishop, Peter Kraft, Abrar A. Qureshi, Peter A. Kanetsky, Nicholas K. Hayward, David J. Hunter, Qingyi Wei and Jiali Han

in Carcinogenesis

Volume 35, issue 9, pages 2097-2101
Published in print September 2014 | ISSN: 0143-3334
Published online June 2014 | e-ISSN: 1460-2180 | DOI:
Identification of a melanoma susceptibility locus and somatic mutation in TET2

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


Although genetic studies have reported a number of loci associated with melanoma risk, the complex genetic architecture of the disease is not yet fully understood. We sought to identify common genetic variants associated with melanoma risk in a genome-wide association study (GWAS) of 2298 cases and 6654 controls. Thirteen of 15 known loci were replicated with nominal significance. A total of 69 single-nucleotide polymorphisms (SNPs) were selected for in silico replication in two independent melanoma GWAS datasets (a total of 5149 cases and 12 795 controls). Seven novel loci were nominally significantly associated with melanoma risk. These seven SNPs were further genotyped in 234 melanoma cases and 238 controls. The SNP rs4698934 was nominally significantly associated with melanoma risk. The combined odds ratio per T allele = 1.18; 95% confidence interval (1.10–1.25); combined P = 7.70 × 10 7. This SNP is located in the intron of the TET2 gene on chromosome 4q24. In addition, a novel somatic mutation of TET2 was identified by next-generation sequencing in 1 of 22 sporadic melanoma cases. TET2 encodes a member of TET family enzymes that oxidizes 5-methylcytosine to 5-hydroxymethylcytosine (5hmC). It is a putative epigenetic biomarker of melanoma as we previously reported, with observation of reduced TET2 transcriptional expression. This study is the first to implicate TET2 genetic variation and mutation in melanoma.

Journal Article.  4272 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.